Collecting stool and blood samples from cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

ARGONAUT is a longitudinal observational study aimed at enrolling up to 5,000 advanced-stage cancer patients from diverse racial backgrounds. The study focuses on collecting stool and blood samples to develop precision microbiome medicines and identify cancer-specific biomarkers that can guide treatment decisions. It will profile four types of solid tumors: non-small cell lung cancer, triple negative breast cancer, colorectal cancer, and pancreatic cancer, while also including healthy control subjects. The data gathered will help optimize microbiome therapies for better patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Men or women who are ≥ 18 years old with stage III or stage IV non-small cell lung cancer (NSCLC), colorectal cancer, triple-negative breast cancer, or pancreatic cancer treated by a particular cancer treatment for the first time, OR healthy subjects undergoing a standard of care colonoscopy
* Subjects able to provide written informed consent

Exclusion Criteria:

* Subjects with known HIV, Hepatitis A, Hepatitis B, Hepatitis C, or SARS-CoV2
* Subjects without the mental capacity to complete either a written or online questionnaire, alone or with assistance, or make sound decisions
* Women who are pregnant or who plan on becoming pregnant
* Women who are nursing

Where it's running

• Knowledge Research Center
  Orange, California, United States Recruiting
• SDG Clinical Research, Inc
  San Diego, California, United States Recruiting
• Persephone Biosciences, Inc.
  San Diego, California, United States Recruiting
• L&A Morales Healthcare, Inc
  Miami, Florida, United States Recruiting
• Baton Rouge General Medical Center
  Baton Rouge, Louisiana, United States Recruiting
• University Medical Center New Orleans
  New Orleans, Louisiana, United States Recruiting

Study contacts

• Study coordinator: Stephanie Culler, PhD
• Email: support@persephonebiome.com
• Phone: 858-682-4777

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• First-in-human test of HH160 in people with advanced solid tumors

  HH160 is being tested to see if it is safe and how it behaves in the body, to see if it has early signs of helping various advanced cancers in adults.

  Recruiting at 3 sites Phase 1 Huahui Health · Waratah, New South Wales and 2 other locations · NCT07623369

• IDE034 for adults with advanced solid tumors that express B7-H3 and PTK7

  This trial will test IDE034 to see if it is safe and works in adults with advanced or metastatic solid tumors that express B7-H3 and PTK7.

  Recruiting at 26 sites Phase 1 IDEAYA Biosciences · Duarte, California and 25 other locations · NCT07503808

• Targeted radioligand [177Lu]Lu-DFC413 for advanced pancreatic, lung, breast, and colorectal cancers

  This will test a new targeted radioactive medicine, [177Lu]Lu-DFC413 (with a PET tracer [68Ga]Ga-NNS309), to see if it is safe and shows activity in adults with advanced pancreatic, lung, breast, or colorectal cancer.

  Recruiting at 9 sites Phase 1 Novartis · Princeton, New Jersey and 8 other locations · NCT07261631

• Evaluating a new treatment for advanced pancreatic, lung, breast, and colorectal cancers

  This study is testing a new type of radiation treatment for people with advanced pancreatic, lung, breast, and colorectal cancers to see if it is safe and effective.

  Recruiting at 29 sites Phase 1 Novartis · Birmingham, Alabama and 28 other locations · NCT06562192

• Testing ZM008 alone and with Pembrolizumab in patients with advanced solid tumors

  This study is testing a new treatment called ZM008, alone and with another drug called Pembrolizumab, to see if it can help patients with advanced solid tumors who have run out of other treatment options.

  Recruiting at 3 sites Phase 1 Zumutor Biologics Inc. · Boston, Massachusetts and 2 other locations · NCT06451497

• Testing MGC026 in patients with advanced solid tumors

  This study is testing a new treatment called MGC026 to see if it can help adults with advanced solid tumors that can't be removed or have spread to other parts of the body.

  Recruiting at 12 sites Phase 1 MacroGenics · Los Angeles, California and 11 other locations · NCT06242470

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.